NEW YORK NODE

NEW YORK NODE (formerly Greater New York Node)

Principal Investigators:
Edward V. Nunes, M.D. [email]
 Professor of Clinical Psychiatry
Columbia University, College of Physicians and Surgeons
1051 Riverside Dr., Box 51
New York, NY 10032

John Rotrosen, M.D. [email]
Professor
Department of Psychiatry
New York University School of Medicine
One Park Ave., 8th Floor
New York, NY 10016
NIDA web site

The New York Node was established in 2010 and originally named the Greater New York Node, created by combining into a single node both the Regional Research and Training Centers and the Community Treatment Programs of the original nodes in New York and Long Island. It was renamed the New York Node in 2020.

RRTCs: New York State Psychiatric Institute, Columbia University and New York University School of Medicine


NEW YORK NODE PROTOCOL INVOLVEMENT
CTN-0001 Buprenorphine/Naloxone versus Clonidine for Inpatient Opiate Detoxification
CTN-0002 Buprenorphine/Naloxone versus Clonidine for Outpatient Opiate Detoxification
CTN-0003 Suboxone (Buprenorphine/Naloxone) Taper: A Comparison of Taper Schedules
CTN-0007 Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics
CTN-0008 Assessment of the National Drug Abuse Clinical Trials Network: A Baseline for Investigating Diffusion of Innovation
CTN-0009 Smoking Cessation Treatment with Transdermal Nicotine Replacement Therapy in Substance Abuse Rehabilitation Programs
CTN-0012 Characteristics of Screening, Evaluation, and Treatment of HIV/AIDS, Hepatitis C Viral Infections, and Sexually Transmitted Infections in Substance Abuse Treatment Programs
CTN-0015 Women's Treatment for Trauma and Substance Use Disorders
CTN-0016 Patient Feedback: A Performance Improvement Study in Outpatient Addiction Treatment Settings
CTN-0018 Reducing HIV/STD Risk Behaviors: A Research Study for Men in Drug Abuse Treatment
CTN-0019 Reducing HIV/STD Risk Behaviors: A Research Study for Women in Drug Abuse Treatment
CTN-0021 Motivational Enhancement Treatment to Improve Treatment Engagement and Outcome for Spanish-Speaking Individuals Seeking Treatment for Substance Abuse
CTN-0028 Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents (with Substance Use Disorder)
CTN-0029 Attention Deficit Hyperactivity Disorder (ADHD) in Adult Smokers
CTN-0030

Prescription Opioid Addiction Treatment Study (POATS)

CTN-0030-A-1 Collection of Economic Data for the Prescription Opioid Addiction Treatment Study
CTN-0031-A-2 The Role of Alcohol Consumption Classifications of Alcohol Use Disorders: A Clinical Study
CTN-0037 Stimulant Reduction Intervention Using Dosed Exercise (STRIDE)
CTN-0037-A-1 Site Influences on Treatment Effects - Exercise as a Treatment for Substance Use Disorders
CTN-0044 Web-Delivery of Evidence-Based, Psychosocial Treatment for Substance Use Disorders
CTN-0044-A-2 Acceptability of a Web-delivered, Evidence-based, Psychosocial Intervention among Individuals with Substance Use Disorders who Identify as American Indian/Alaska Native
CTN-0044-A-3 Web-Tx Organizational and Practitioner Follow-Up
CTN-0045-Ot Rates of HIV Testing and Barriers to Testing in African Americans Receiving Substance Abuse Treatment
CTN-0047 Screening, Motivational Assessment, Referral, and Treatment in Emergency Departments (SMART-ED)
CTN-0048 Cocaine Use Reduction with Buprenorphine (CURB)
CTN-0051 Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT)
CTN-0051-A-1 Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT) Genetics Study
CTN-0051-A-2 Treatment-As-Usual Opioid Use Outcomes Following Discharge from Detoxification and Short-Term Residential Programs Affiliated with CTN-0051
CTN-0059 Tobacco, Alcohol, Prescription Medications, and Substance Use/Misuse Brief Screen/Assessment Tool
CTN-0062ot A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements into the Electronic Health Record in Large Primary Care Settings (CDE-EHR-PC)
CTN-0062Ot-A1 Implementing the Tobacco, Alcohol, Prescription Medication, and Other Substances (TAPS) Tool in Rural Federally-Qualified Health Centers
CTN-0068 Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder
CTN-0079 Initiating Extended-Release Buprenorphine for Opioid Use Disorder in Rural Emergency Department Settings
CTN-0082

Implementation Survey of PrEP and Opioid Use Related Services In STI Clinics and Community Based Organizations (CBOs)
CTN-0096

Culturally Centered MAT for OUD Implementation Facilitation for Primary Care and Addiction Treatment Programs Serving American Indian/Alaska Natives(NIH HEAL Initiative)
CTN-0097

Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): Improving the Real-World Effectiveness of Injection Naltrexone for Opioid Use Disorder (NIH HEAL Initiative)
CTN-0100

Optimizing Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (NIH HEAL Initiative)
CTN-0112

Optimal Policies to Improve Methadone Maintenance Adherence Longterm (OPTIMMAL)
Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 3/2021 -- http://ctndisseminationlibrary.org/nodes/gnynode.htm
info@ctndisseminationlibrary.org